U.S. Bancorp | BTIG to Host Turn Therapeutics for Virtual Fireside Chat
Stocks in this Quantisnow insightHealth Care
Historical context for TTRX
Across the 24 sessions after earlier TTRX headlines, the stock closed higher 8 times and lower 16 times, with a median move of 6.3% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | TTRX | SPY |
|---|---|---|---|
| Sep 10, 2026 | Turn Therapeutics to Present at Stifel 2026 Virtual Immunology and Inflammation Forum | -2.7% | -0.6% |
| Sep 9, 2026 | Turn Therapeutics Appoints Former CDC Director Robert R. Redfield, M.D., as Chief Scientific Officer | +8.6% | -0.5% |
| Aug 13, 2026 | Turn Therapeutics Provides Corporate Updates and Reports Second Quarter 2026 Financial Results | -6.5% | +0.7% |
| Jul 28, 2026 | Turn Therapeutics to Ring the Nasdaq Closing Bell on Monday, August 10, 2026 | -1.0% | +0.2% |
| Jul 7, 2026 | Turn Therapeutics Announces Final Stage 2 Design and Data-Driven Expansion of GX-03 Phase 2 Program in Atopic Dermatitisand 1 other headline that session | +26.3% | -0.5% |
| Jun 1, 2026 | Turn Therapeutics Reports Interim Analysis Findings and Adaptive Optimization Strategy from Phase 2 GX-03 Trial in Moderate-to-Severe Atopic Dermatitis | +21.7% | +0.3% |
Quantisnow market dataNASDAQ
TTRX
Turn Therapeutics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
Get push alerts for TTRX
Full TTRX profile on Quantisnow Follow TTRX and get a push notification the moment its next story breaks.